Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21709370 | 0.88 | ALOX5 (0.34) | NUDT1ALOX5PRKDC | |
| SCHEMBL21709369 | 0.87 | NUDT1 (0.36) | NUDT1ALOX5SCN9A | |
| SCHEMBL21709440 | 0.87 | NUDT1 (0.45) | NUDT1ALOX5PRKDCGGPS1JAK2 | |
| SCHEMBL24801448 | 0.86 | NUDT1 (0.32) | NUDT1 | |
| SCHEMBL9916956 | 0.86 | ALOX5 (0.44) | ALOX5PRKDCGGPS1 | |
| SCHEMBL9916517 | 0.86 | ALOX5 (0.44) | ALOX5PRKDCGGPS1 | |
| SCHEMBL6372706 | 0.86 | ALOX5 (0.44) | ALOX5PRKDCGGPS1 | |
| SCHEMBL9916507 | 0.86 | ALOX5 (0.44) | ALOX5PRKDCGGPS1 | |
| SCHEMBL30907081 | 0.86 | ALOX5 (0.44) | ALOX5PRKDCGGPS1 | |
| SCHEMBL9916513 | 0.86 | ALOX5 (0.44) | ALOX5PRKDCGGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048207-A1 | COMPOUNDS WITH ARYLAMINE STRUCTURES | DDT, NAT1, INMT | NUDT1 15/4885ALOX5 3104/4885PRKDC 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.